Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Quick facts
Marketed products
- Mavenclad® · Immunology; Neurology
Mavenclad (cladribine) is a purine nucleoside analog that depletes lymphocytes by interfering with DNA synthesis and repair in dividing cells.
Phase 3 pipeline
- Cladribine High Dose · Oncology, Immunology
Cladribine is a purine nucleoside analog that depletes lymphocytes by being incorporated into DNA and causing strand breaks, leading to selective destruction of immune cells. - Cladribine Low Dose · Immunology
Cladribine is a purine nucleoside analog that depletes lymphocytes by inhibiting ribonucleotide reductase and inducing apoptosis in dividing cells. - Coriogonadotropin alfa · Reproductive Medicine / Fertility
Coriogonadotropin alfa is a recombinant human chorionic gonadotropin (hCG) analog that stimulates the corpus luteum to produce progesterone for luteal phase support in assisted reproductive technology. - Palcebo · Other
Phase 2 pipeline
- Enpatoran high dose
- Enpatoran low dose · Diabetes
Enpatoran low dose is a small molecule that acts as a selective and potent inhibitor of the sodium-glucose cotransporter 2 (SGLT2). - M5049 high dose
- M5049 low dose
- M5049 medium dose
Phase 1 pipeline
- [14C]Berzosertib
- [14C]enpatoran microdose
- [14C]enpatoran microtracer
- Cataflam DD®
- Deflox®
- Eutirox®
- Evobruitnib · Other
- Evobrutinib MR-T adapated
- Evobrutinib MR-T1
- Evobrutinib MR-T2
- Evobrutinib MR-T3
- Evobrutinib MR-T4
- Evobrutinib MUPS-C1
- Evobrutinib MUPS-C2
- Evobrutinib MUPS-C3
- Evobrutinib MUPS-C4
- Glucophage® XR Reference
- Glucophage® XR RM Test
- M2951 High Dose
- M2951 Low Dose
- M5542
- M9140
- Pergoveris FD
- Pergoveris Liquid
- Puran T4®
- Reference Euthyrox®
- Reference Eutirox®
- Reference Glucophage® XR
- Test Euthyrox®
- Test Eutirox®
- Test Glucophage® XR
- Tuvusertib [14C]Tuvusertib microtracer
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: